Working with TipRanks
Follow Us
Stock Ideas
Daily Updates
Calendars
Education
About Us
Working with TipRanks
Follow Us
Krystal Biotech (KRYS)
NASDAQ:KRYS
Krystal Biotech (KRYS) Stock Price & Analysis
287 Followers
KRYS Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$49.17 - $124.23
Previous Close$124.2
Volume325.99K
Average Volume (3M)271.51K
Market Cap
$3.20B
Enterprise Value$2.86B
Total Cash (Recent Filing)$350.39M
Total Debt (Recent Filing)$8.76M
Price to Earnings (P/E)-23.5
Beta0.92
Next Earnings
Aug 07, 2023EPS Estimate
-$1.31Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.28
Shares Outstanding25,799,738
10 Day Avg. Volume614,902
30 Day Avg. Volume271,515
Standard Deviation0.17
R-Squared0.07
Alpha0.05
Financial Highlights & Ratios
Price to Book (P/B)6.21
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-29.10
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-27.49
Forecast
1Y Price Target
$141.00Price Target Upside15.77% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
Krystal Biotech News
Pre-EarningsIs KRYS a Buy, Before Earnings?
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Product Insights
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
KRYS FAQ
What was Krystal Biotech’s price range in the past 12 months?
Krystal Biotech lowest stock price was $49.17 and its highest was $124.23 in the past 12 months.
What is Krystal Biotech’s market cap?
Currently, no data Available
When is Krystal Biotech’s upcoming earnings report date?
Krystal Biotech’s upcoming earnings report date is Aug 07, 2023 which is in 62 days.
How were Krystal Biotech’s earnings last quarter?
Krystal Biotech released its earnings results on May 08, 2023. The company reported -$1.76 earnings per share for the quarter, missing the consensus estimate of -$1.438 by -$0.322.
Is Krystal Biotech overvalued?
According to Wall Street analysts Krystal Biotech’s price is currently Undervalued.
Does Krystal Biotech pay dividends?
Krystal Biotech does not currently pay dividends.
What is Krystal Biotech’s EPS estimate?
Krystal Biotech’s EPS estimate is -$1.31.
How many shares outstanding does Krystal Biotech have?
Krystal Biotech has 25,799,738 shares outstanding.
What happened to Krystal Biotech’s price movement after its last earnings report?
Krystal Biotech reported an EPS of -$1.76 in its last earnings report, missing expectations of -$1.438. Following the earnings report the stock price went up 4.048%.
Which hedge fund is a major shareholder of Krystal Biotech?
Among the largest hedge funds holding Krystal Biotech’s share is Deerfield Management Company, LP. It holds Krystal Biotech’s shares valued at 25M.
---
Krystal Biotech Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$141.00 (15.77% Upside)
$141.00 (15.77% Upside)
Blogger Sentiment
Bullish
KRYS Sentiment 80%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 196.5K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $11.6M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 3.8%
Last 30 Days ▲ 38.6%
Last 30 Days ▲ 38.6%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
107.31%
12-Months-Change
Fundamentals
Return on Equity
-26.07%
Trailing 12-Months
Asset Growth
-13.78%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Krystal Biotech
Krystal Biotech, Inc. is a gene therapy company, which engages in developing and commercializing treatment for patients suffering from dermatological diseases. It developed a gene therapy platform, which company refer to as the Skin TARgeted Delivery platform, or STAR-D platform, that consists of a patent pending engineered viral vector based on herpes simplex virus 1, or HSV-1, and skin-optimized gene transfer technology, to develop off-the-shelf treatments for dermatological diseases for which company believe there are no known effective treatments. The company was founded by Suma M. Krishnan in December 2017 and is headquartered in Pittsburgh, PA.
---
Top 5 ETFs holding KRYS
Vanguard Total Stock Market ETF
$57.90M
iShares Biotechnology ETF
$17.63M
Vanguard Health Care ETF
$5.28M
Invesco DWA Healthcare Momentum ETF
$3.82M
iShares Core S&P Total U.S. Stock Market ETF
$2.60M
Up to five ETFs with an Outperform Smart Score that hold KRYS. The ETFs are listed according to market value of KRYS within the ETF
---
Accelerate Diagnostics
―
Bellicum Pharmaceuticals
―
Crispr Therapeutics AG
―
Editas Medicine
―
---